| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
HED-Late was significantly lower in HFpEF compared to the control group of healthy subjects without cardiovascular complications and hypertensive patients (healthy subjects: 15.8±2.5 vs. hypertensive patients: 12.4± 3.1 vs. HFpEF: 9.2±4.8(%/min), p=0.005). When factors related to sympathetic nerve endings function were examined, HED-Late was preserved in HFpEF with atrial fibrillation in the group with oral beta-blocker compared to the group without beta-blocker (12.5±2.3 vs. 3.9±1.3(%/min), p=0.002). These results suggest that oral beta-blocker therapy may preserve cardiac sympathetic function in HFpEF with atrial fibrillation.
|
